Category: Healthcare Innovation

  • Usahasama Global: Inovasi Kolagen Nano Biri-Biri dari Australia Kini Menembusi Dunia

    Usahasama Global: Inovasi Kolagen Nano Biri-Biri dari Australia Kini Menembusi Dunia

    Dua pemain industri yang berakar umbi di Malaysia serta disenaraikan di bursa antarabangsa kini bergabung tenaga untuk memacu inovasi dalam sektor kesihatan global, anti-penuaan dan kesejahteraan. Holista Colltech Limited (ASX: HCT) dan Swang Chai Chuan Limited (HKEX:2321) secara rasmi mengumumkan penubuhan usahasama strategik 50:50 melalui Ovicoll Pty Ltd, sekali gus menandakan satu langkah penting dalam usaha memperluaskan kejayaan serantau mereka ke pasaran global.

    Kerjasama ini memberi tumpuan kepada pembangunan kemudahan pengeluaran kolagen nano berasaskan biri-biri yang berteknologi tinggi di Collie, Australia Barat. Usahasama ini menggabungkan kekuatan kedua-dua pihak, iaitu kepakaran saintifik serta inovasi bioteknologi daripada Holista Colltech yang tersenarai di Australia, bersama kekuatan modal dan rangkaian pengedaran luas Swang Chai Chuan yang tersenarai di Hong Kong.

    Antara kelebihan utama perikatan strategik ini ialah pembangunan kolagen berasaskan ovine (biri-biri) yang bersifat neutral dari segi budaya dan agama, menjadikannya diterima secara universal serta berpotensi sebagai alternatif “halal” untuk pasaran global. Selain itu, kemudahan ini turut memanfaatkan kelebihan biosekuriti bertaraf dunia di Australia, yang menempatkan satu-satunya populasi biri-biri di dunia yang diperakui bebas Scrapie dan mempunyai risiko BSE yang sangat rendah menurut Pertubuhan Kesihatan Haiwan Sedunia (WOAH).

    Keunikan ini diperkukuh lagi dengan kawalan sempadan ketat Australia sejak penubuhan persekutuannya pada tahun 1901, yang membantu mengekalkan status bebas penyakit tersebut. Usahasama Ovicoll Pty Ltd ini turut direka untuk mempercepatkan pengembangan pasaran global dengan memanfaatkan kekuatan gabungan kedua-dua syarikat dalam penembusan pasaran antarabangsa.

    Sebagai sebahagian daripada strategi komersial, Holista turut memeterai perjanjian dengan Regenerex Pharma, sebuah syarikat yang sedang berkembang dalam sektor pembalut luka, bagi memperluaskan aplikasi teknologi kolagen ini dalam bidang perubatan dan penjagaan kesihatan.

    Holista Colltech Limited (ASX: HCT) ialah syarikat kesihatan dan kesejahteraan yang disenaraikan di Australia dengan operasi utama di Malaysia. Syarikat ini memberi tumpuan kepada penyelesaian bioteknologi berasaskan sains merangkumi suplemen pemakanan, bahan makanan sihat, kolagen ovine dan kawalan jangkitan.

    Sementara itu, Swang Chai Chuan Limited (HKEX:2321) merupakan peneraju dalam sektor barangan pengguna cepat laris (FMCG) yang disenaraikan di Hong Kong. Kumpulan ini menyediakan perkhidmatan pengedaran, logistik dan pergudangan menyeluruh di Malaysia bagi pelbagai produk makanan, minuman dan barangan isi rumah.

  • IJN Reaches Pinnacle of Digital Maturity as Malaysia’s First Stage 7 EMRAM Hospital

    IJN Reaches Pinnacle of Digital Maturity as Malaysia’s First Stage 7 EMRAM Hospital

    Institut Jantung Negara (IJN) continues to spearhead Malaysia’s digital healthcare transformation as the first hospital in the country to achieve Stage 7 validation under the Healthcare Information and Management Systems Society (HIMSS) Electronic Medical Record Adoption Model (EMRAM). Developed by HIMSS, EMRAM is a globally recognized eight-stage framework that assesses how effectively hospitals adopt and integrate Electronic Medical Records (EMR) into clinical practice. The model evaluates not only the implementation of digital systems but also how deeply these systems are embedded in daily workflows to enhance patient safety, clinical documentation, medication management, clinical decision support, data analytics, and paperless operations.

    Stage 7 represents the highest level of digital maturity, signifying a fully digital, paperless hospital environment supported by advanced data analytics and robust governance structures. Hospitals validated at this level demonstrate optimized clinical workflows, reduced medical errors, standardized processes, and data-driven decision-making. Achieving Stage 7 requires a rigorous international validation process conducted by HIMSS, including detailed electronic documentation reviews, live system demonstrations, workflow validation, and interviews with clinical teams to ensure digital systems are fully integrated and effectively utilized in patient care.

    Prof. Dato’ Sri Dr Mohamed Ezani Md Taib, Chief Executive Officer of IJN, said this milestone reflects the hospital’s long-standing commitment to digital excellence and patient safety. He emphasized that Stage 7 validation confirms that IJN’s digital systems are not only advanced but fully embedded into the delivery of cardiovascular care. The validation empowers clinicians with real-time, accurate information, supporting safer, more efficient, and higher-quality outcomes for patients.

    With this achievement, IJN operates in a fully paperless environment where clinical documentation, medication management, and care coordination are seamlessly integrated across the continuum of care. Advanced analytics capabilities enable real-time clinical surveillance, performance monitoring, and continuous quality improvement. Prof. Dato’ Sri Dr Alwi Mohamed Yunus, Director of Health Informatics and Senior Consultant Cardiothoracic Surgeon at IJN, highlighted that reaching Stage 7 demonstrates that digital transformation is deeply embedded within the hospital’s clinical culture.

    He added that IJN’s clinical teams are equipped with actionable insights at the point of care, enabling them to continuously refine treatment pathways and improve patient outcomes. As one of a select group of hospitals worldwide to attain EMRAM Stage 7 status, IJN sets a new national benchmark in digital healthcare excellence and reinforces its position as a regional leader in technology-enabled cardiovascular care.

  • Cempaka Cahaya Introduces CarePod, Next-Generation AI-Enabled Preventive Healthcare Kiosk

    Cempaka Cahaya Introduces CarePod, Next-Generation AI-Enabled Preventive Healthcare Kiosk

    Cempaka Cahaya Sdn. Bhd. has officially launched CarePod, a state-of-the-art AI-enabled preventive healthcare kiosk designed to enhance early disease detection, structured medical screening, and digitally integrated consultations across community settings in Malaysia. The launch was attended by the Guest of Honour, Dato’ Dr. Suhaimi bin Ibrahim, Pengerusi KOBENA, highlighting strong institutional and cross-sector support for digital transformation in primary healthcare services.

    Engineered by DR Solutions, the health-technology subsidiary of Cempaka Cahaya, CarePod is a vertically integrated platform that ensures full governance from system architecture to field deployment. The kiosk offers real-time vital sign monitoring, Point-of-Care Testing (FBC, biochemistry panels, HbA1c), rapid infectious disease screening for Malaria, Influenza, and Dengue, AI-assisted clinical workflow, secure teleconsultation, and digital referral pathways. This innovative model decentralizes preventive healthcare while maintaining clinical oversight, data security, and structured accountability.

    The CarePod platform is supported by QuantumNexis Sdn. Bhd., a subsidiary of Healthcare Triangle Inc. (NASDAQ: HCTI), providing enterprise-grade cloud infrastructure, cybersecurity, and scalable digital health architecture. Additionally, collaboration with University of Malaya ensures evidence-based validation, NCD risk profiling, infectious disease analytics, and continuous system refinement through academic oversight.

    According to Dr. Balachandran Krishnan, CEO of Cempaka Cahaya Sdn. Bhd., “CarePod represents a strategic step towards shifting Malaysia’s healthcare from reactive treatment to proactive prevention. By integrating diagnostics, infectious disease screening, AI-driven workflow, and teleconsultation, we strengthen early detection capabilities and improve healthcare accessibility nationwide.” CarePod enables early assessment of hypertension, cardiovascular risks, diabetes, metabolic disorders, and acute medical conditions, particularly benefiting semi-urban and rural communities.